2025 · Abstract/Manuscript · Yes
27
Total Publications
5
Abstract/Manuscript
1
Oral Presentation
21
Poster Presentation
2025 · Abstract/Manuscript · Derek Gazis
Cardiovascular risk assessment tools are insufficient for patients with metabolic dysfunction associated steatotic liver disease.
Read more →2025 · Poster Presentation · Yes · Hepatology
Clinical Characteristics of Patients With Presumed MASLD Who Meet Met-ALD Criteria in the TARGET-NASH Cohort.
Read more →2025 · Poster Presentation · Pharma Partner · Hepatology
Relationship between non-invasive tests, clinical outcomes and liver biopsy among people with MASH under real-world conditions.
Read more →2024 · Poster Presentation · University of Birmingham (UK) · Hepatology
Stability of the NASH-CHECK patient-reported outcome measure over time in patients with metabolic dysfunction-associated steatotic liver disease and stable clinical status.
Read more →2024 · Poster Presentation · Yes · Hepatology
A prospective assessment of the impact of decompensation of cirrhosis on patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease.
Read more →2024 · Poster Presentation · Pharma Partner · Hepatology
Time to Disease Progression and All-Cause Mortality in Adult MASH Patients in Real-World US Cohort.
Read more →2024 · Poster Presentation · Pharma Partner · Hepatology
Characteristics of adult MASH patients and factors associated with MASH-relevant clinical endpoints in a real-world US cohort.
Read more →2024 · Poster Presentation · University of Birmingham (UK) · Hepatology
Real-World Use of Glucagon-Like Peptide 1 Receptor Agonists in Patients with MASLD: A Cross-Sectional Analysis from TARGET-NASH.
Read more →2024 · Poster Presentation · University of Birmingham (UK) · Hepatology
A prospective assessment of disease progression impact on patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease.
Read more →2024 · Poster Presentation · Pharma Partner · Hepatology
Relationship between liver biopsy fibrosis stage and clinical outcomes among persons with MASLD/MASH.
Read more →2024 · Oral Presentation · Yes · Hepatology
Use of glucagon-like peptide 1 receptor agonists in patients with MASLD in a real-world setting is associated with slower disease progression and lower all-cause mortality.
Read more →2023 · Abstract/Manuscript · Yes
Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort.
Read more →2022 · Poster Presentation · Pharma Partner · Hepatology
Longitudinal ALT Trajectories are Generally Stable Among Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): An Investigation Using Artificial Recurrent Neural Networks.
Read more →2021 · Poster Presentation · Pharma Partner · Hepatology
Determination of Optimal Thresholds for Significant Fibrosis in NAFLD Using Non-Invasive Tests from TARGET-NASH Study.
Read more →2021 · Abstract/Manuscript · Pharma Partner
Liver Biopsy in the Real World—Reporting, Expert Concordance and Correlation with a Pragmatic Clinical Diagnosis.
Read more →2020 · Poster Presentation · Yes · Hepatology
A Pragmatic Clinical Prognostic Classification Suitable for Universal Application Stratifies Patients with NAFLD by Risk of Mortality and Both Hepatic and Extrahepatic Outcomes.
Read more →2020 · Poster Presentation · University of Birmingham (UK) · Hepatology
Heterogeneous Documentation and Poor Concordance of NASH Pathology May Limit its Clinical Utility in Real-World Practice.
Read more →2020 · Poster Presentation · Yes · Hepatology
Fibrosis Assessed by Non-Invasive Tests is Similar to Liver Biopsy for Predicting Clinical Outcomes: A TARGET-NASH Study.
Read more →2020 · Poster Presentation · Pharma Partner · Hepatology
Predicting advanced fibrosis using non-invasive clinical tests and modern machine learning methods in TARGET-NASH.
Read more →2019 · Poster Presentation · Pharma Partner · Hepatology
Routinely Available Noninvasive Tests Perform Well in Identifying Patients with Advanced Fibrosis Due to NASH: Data from the TARGET-NASH Observational Cohort.
Read more →2019 · Poster Presentation · Emory · Hepatology
Patterns of Medication Use Among Adult Patients with Elevated Serum ALT Levels in Patients with NAFLD: TARGET-NASH.
Read more →2019 · Poster Presentation · R&D · Hepatology
Management of Hepatocellular Carcinoma (HCC) in a Real Life Multinational, Longitudinal, Observational Study (TARGET-HCC).
Read more →2019 · Poster Presentation · R&D · Hepatology
Regional, racial/ethnic, and socioeconomic disparities and treatment outcomes in patients with hepatocellular carcinoma (HCC) in the US.
Read more →2018 · Poster Presentation · R&D · Hepatology
Nonalcoholic Fatty Liver Disease in Children in the U.S.: Clinical Characteristics of Participants Enrolled in TARGET-NASH.
Read more →2017 · Poster Presentation · Approval & Commercialization · Hepatology